• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

降低强度的预处理增加了严重 cGVHD 的风险:多中心环境下 cGVHD 风险因素的识别。

Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting.

机构信息

Department of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Department of Hematology, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.

出版信息

Med Oncol. 2018 Apr 25;35(6):79. doi: 10.1007/s12032-018-1127-2.

DOI:10.1007/s12032-018-1127-2
PMID:29696461
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5918523/
Abstract

Chronic graft-versus-host disease (cGVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Aim is to identify risk factors for the development of cGVHD in a multicenter setting. Patients transplanted between 2000 and 2006 were analyzed (n = 820). Donors were HLA-identical siblings (57%), matched unrelated donors (30%), and HLA-A, B or DR antigen mismatched (13%). Reduced intensity conditioning (RIC) was given to 65% of patients. Overall incidence of cGVHD was 46% for patients surviving more than 100 days after HSCT (n = 747). Older patient age [HR 1.15, p < 0.001], prior acute GVHD [1.30, p = 0.024], and RIC [1.36, p = 0.028] increased overall cGVHD. In addition, RIC [4.85, p < 0.001], prior aGVHD [2.14, p = 0.001] and female donor to male recipient [1.80, p = 0.008] increased the risk of severe cGVHD. ATG had a protective effect for both overall [0.41, p < 0.001] and severe cGVHD [0.20, p < 0.001]. Relapse-free survival (RFS) was impaired in patients with severe cGVHD. RIC, prior aGVHD, and female-to-male donation increase the risk of severe cGVHD. ATG reduces the risk of all grades of cGVHD without hampering RFS. GVHD prophylaxis may be tailored according to the risk profile of patients.

摘要

慢性移植物抗宿主病(cGVHD)仍然是异基因造血干细胞移植(HSCT)后发病率和死亡率的主要原因。目的是在多中心环境中确定 cGVHD 发展的危险因素。分析了 2000 年至 2006 年间移植的患者(n=820)。供体为 HLA 完全匹配的同胞(57%)、匹配的无关供体(30%)和 HLA-A、B 或 DR 抗原错配(13%)。65%的患者接受了强度降低的调理。HSCT 后 100 天以上存活的患者中 cGVHD 的总体发生率为 46%(n=747)。患者年龄较大[HR 1.15,p<0.001]、急性移植物抗宿主病(GVHD)既往史[1.30,p=0.024]和强度降低的调理[1.36,p=0.028]均增加了整体 cGVHD 的发生率。此外,强度降低的调理[4.85,p<0.001]、急性 GVHD 既往史[2.14,p=0.001]和女性供体至男性受体[1.80,p=0.008]增加了严重 cGVHD 的风险。ATG 对整体[0.41,p<0.001]和严重 cGVHD [0.20,p<0.001]均具有保护作用。有严重 cGVHD 的患者无复发生存率(RFS)受损。严重 cGVHD 患者的 RIC、急性 GVHD 既往史和女性供体至男性受体增加了风险。ATG 降低了所有等级 cGVHD 的风险,而不会影响 RFS。根据患者的风险状况,可以调整 GVHD 的预防措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48aa/5918523/adb50a1f7650/12032_2018_1127_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48aa/5918523/ad7f0eb0ba86/12032_2018_1127_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48aa/5918523/fd6dde449a62/12032_2018_1127_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48aa/5918523/bbfd22c2b744/12032_2018_1127_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48aa/5918523/adb50a1f7650/12032_2018_1127_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48aa/5918523/ad7f0eb0ba86/12032_2018_1127_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48aa/5918523/fd6dde449a62/12032_2018_1127_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48aa/5918523/bbfd22c2b744/12032_2018_1127_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48aa/5918523/adb50a1f7650/12032_2018_1127_Fig4_HTML.jpg

相似文献

1
Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting.降低强度的预处理增加了严重 cGVHD 的风险:多中心环境下 cGVHD 风险因素的识别。
Med Oncol. 2018 Apr 25;35(6):79. doi: 10.1007/s12032-018-1127-2.
2
Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.KIR基因型的供受者匹配可减少慢性移植物抗宿主病,且缺乏抑制性KIR配体可预防清髓性、HLA匹配的造血细胞移植后的复发。
PLoS One. 2016 Jun 24;11(6):e0158242. doi: 10.1371/journal.pone.0158242. eCollection 2016.
3
Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program.中国造血干细胞捐献者资料库中无关供者造血干细胞移植后移植物抗宿主病的危险因素
Ann Transplant. 2017 Jun 27;22:384-401. doi: 10.12659/aot.902805.
4
Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.谷胱甘肽S-转移酶T1基因不匹配会增加异基因干细胞移植后发生移植物抗宿主病和死亡的风险。
Biol Blood Marrow Transplant. 2014 Sep;20(9):1356-62. doi: 10.1016/j.bbmt.2014.05.008. Epub 2014 May 17.
5
Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.不同供者来源的缓解期急性白血病行异基因造血干细胞移植后应用胸腺球蛋白的影响。
Blood Adv. 2019 Jan 22;3(2):105-115. doi: 10.1182/bloodadvances.2018025643.
6
Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.脐带血和匹配同胞供者异基因造血细胞移植后急性和慢性移植物抗宿主病的危险因素
Biol Blood Marrow Transplant. 2016 Jan;22(1):134-40. doi: 10.1016/j.bbmt.2015.09.008. Epub 2015 Sep 11.
7
Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.非亲缘供者减低预处理强度异基因造血干细胞移植后Ⅱ-Ⅳ级急性移植物抗宿主病的危险因素:一项单中心研究
Bone Marrow Transplant. 2008 Feb;41(4):399-405. doi: 10.1038/sj.bmt.1705913. Epub 2007 Nov 5.
8
Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.影响异基因造血系统恶性肿瘤移植后结局的预后因素:一项随机试验的结果。
Biol Blood Marrow Transplant. 2012 Nov;18(11):1716-26. doi: 10.1016/j.bbmt.2012.06.001. Epub 2012 Jun 17.
9
Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.低剂量抗胸腺细胞球蛋白在成人获得性重型再生障碍性贫血无关供者干细胞移植中的有益作用:降低移植物抗宿主病并提高无移植物抗宿主病、无失败生存率
Biol Blood Marrow Transplant. 2017 Sep;23(9):1498-1508. doi: 10.1016/j.bbmt.2017.05.026. Epub 2017 May 26.
10
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.使用白消安、氟达拉滨和抗胸腺细胞球蛋白进行减低强度预处理用于缓解期急性髓系白血病患者接受无关或单倍体相合家庭供者造血细胞移植
Biol Blood Marrow Transplant. 2017 Sep;23(9):1555-1566. doi: 10.1016/j.bbmt.2017.05.025. Epub 2017 May 25.

引用本文的文献

1
Comparison of oral chronic graft-versus-host disease characteristics between patients with malignant and non-malignant hematopoietic disorders.恶性与非恶性造血系统疾病患者口腔慢性移植物抗宿主病特征的比较
BMC Oral Health. 2025 Mar 28;25(1):449. doi: 10.1186/s12903-025-05785-x.
2
Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group.第一代和第二代酪氨酸激酶抑制剂对慢性髓性白血病患者移植物抗宿主病发生的影响:代表波兰成人白血病组的一项回顾性分析
Biomedicines. 2025 Jan 11;13(1):163. doi: 10.3390/biomedicines13010163.
3

本文引用的文献

1
Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.移植前合并症预测急性移植物抗宿主病的严重程度和随后的死亡率。
Blood. 2014 Jul 10;124(2):287-95. doi: 10.1182/blood-2014-01-550566. Epub 2014 May 5.
2
Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.在降低强度的预处理方案中使用抗胸腺细胞球蛋白可实现无长期慢性移植物抗宿主病的高无病生存率。
Biol Blood Marrow Transplant. 2014 Mar;20(3):370-4. doi: 10.1016/j.bbmt.2013.11.030. Epub 2013 Dec 4.
3
Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors.
Associations between acute and chronic graft-versus-host disease.
急、慢性移植物抗宿主病的相关性。
Blood Adv. 2024 Aug 27;8(16):4250-4261. doi: 10.1182/bloodadvances.2024013442.
4
PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT.PTCy 与基于 CNI 的 GVHD 预防方案在 HLA 匹配移植治疗霍奇金淋巴瘤中的对比:来自 EBMT 的 LWP 研究。
Blood Adv. 2024 Aug 13;8(15):3985-3992. doi: 10.1182/bloodadvances.2024013328.
5
Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors.造血干细胞移植后的心血管事件:发生率及危险因素
JACC CardioOncol. 2023 Sep 19;5(6):821-832. doi: 10.1016/j.jaccao.2023.07.007. eCollection 2023 Dec.
6
Low incidence of severe acute and chronic graft-versus-host disease in a long-term retrospective study with ATG Grafalon routine use.在一项长期回顾性研究中,常规使用 ATG Grafalon 后,严重急性和慢性移植物抗宿主病的发生率较低。
Ann Hematol. 2023 Dec;102(12):3587-3591. doi: 10.1007/s00277-023-05479-w. Epub 2023 Oct 3.
7
Allogeneic haematopoietic cell transplants as dynamical systems: influence of early-term immune milieu on long-term T-cell recovery.异基因造血细胞移植作为动态系统:早期免疫环境对长期T细胞恢复的影响。
Clin Transl Immunology. 2023 Jul 13;12(7):e1458. doi: 10.1002/cti2.1458. eCollection 2023.
8
Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.慢性移植物抗宿主病 NIH 共识项目生物学工作组:向慢性移植物抗宿主病个体化治疗的演进之路。
Blood Adv. 2023 Sep 12;7(17):4886-4902. doi: 10.1182/bloodadvances.2022007611.
9
Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan.儿童和青少年急性淋巴细胞白血病慢性移植物抗宿主病的管理:现状与个性化管理计划模型
Front Pediatr. 2022 Feb 18;10:808103. doi: 10.3389/fped.2022.808103. eCollection 2022.
10
Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.抗体药物偶联物加 JAK 抑制剂使 MHC 错配的同种异体造血干细胞移植成为可能。
J Clin Invest. 2021 Dec 15;131(24). doi: 10.1172/JCI145501.
移植前 ATG 对部分不匹配非亲缘供者减低强度造血细胞移植结局的有利影响。
Bone Marrow Transplant. 2014 Feb;49(2):185-9. doi: 10.1038/bmt.2013.168. Epub 2013 Oct 28.
4
Risk factors and organ involvement of chronic GVHD in Japan.日本慢性移植物抗宿主病的危险因素和器官受累情况。
Bone Marrow Transplant. 2014 Feb;49(2):228-35. doi: 10.1038/bmt.2013.151. Epub 2013 Sep 30.
5
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.美国国立卫生研究院对慢性移植物抗宿主病的分类可预测氟达拉滨-白消安-抗胸腺细胞球蛋白预处理方案后异基因造血干细胞移植的结果。
Leuk Lymphoma. 2014 May;55(5):1106-12. doi: 10.3109/10428194.2013.820285. Epub 2014 Feb 4.
6
A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors.高抗胸腺细胞球蛋白剂量增加了非血缘供体减低强度预处理 HSCT 后复发的风险。
Clin Transplant. 2013 Jul-Aug;27(4):E368-74. doi: 10.1111/ctr.12131. Epub 2013 May 22.
7
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.氟达拉滨、卡莫司汀、马法兰和抗胸腺细胞球蛋白用于成人降低毒性预处理和同种异体干细胞移植:结果取决于疾病风险指数,但与年龄、合并症评分、供体类型或人类白细胞抗原错配无关。
Biol Blood Marrow Transplant. 2013 Aug;19(8):1167-74. doi: 10.1016/j.bbmt.2013.05.001. Epub 2013 May 7.
8
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后移植物抗宿主病和移植物抗肿瘤效应。
J Clin Oncol. 2013 Apr 20;31(12):1530-8. doi: 10.1200/JCO.2012.45.0247. Epub 2013 Mar 11.
9
Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.二线系统治疗慢性移植物抗宿主病后的无失败生存。
Blood. 2013 Mar 21;121(12):2340-6. doi: 10.1182/blood-2012-11-465583. Epub 2013 Jan 15.
10
Evaluation of prognostic factors among patients with chronic graft-versus-host disease.慢性移植物抗宿主病患者预后因素的评估。
Haematologica. 2012 Aug;97(8):1187-95. doi: 10.3324/haematol.2011.055244. Epub 2012 Feb 27.